Favorable Figures and a New Collaboration: Ocugen Shows How to End the Week in Style
OCGN

This week Ocugen, Inc. ($OCGN) entered into an agreement with Kemwell Biopharma for the cGMP production of OCU200. This is the new biologic product candidate in preclinical development for the treatment of severe vision-threatening diseases, such as: diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (Wet-AMD). What is the power of…